Steroid Injection in De Quervain Tenosynovitis
Effectiveness of Steroid Injection in Treating Pain in De Quervain Tenosynovitis
1 other identifier
observational
50
1 country
1
Brief Summary
This study is carried out to find out the degree of pain relief achieved with standard treatment as steroid injection as well as its time to onset. It will recruit 50 subjects over a period of 18 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 14, 2019
CompletedFirst Submitted
Initial submission to the registry
February 14, 2022
CompletedFirst Posted
Study publicly available on registry
March 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedMarch 2, 2022
February 1, 2022
3.7 years
February 14, 2022
February 20, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Determine efficacy of steroid injection
a single steroid injection over first dorsal compartment for patients diagnosed with de Quervain tenosynovitis will make effect within 7 days from injection, relieving pain to less or equal than 1 in Visual Analogue Scale (VAS)
7 days
Interventions
Steroid injection effectiveness will be determined by relief of pain scored by patient using Visual Analogue Scale (VAS). Data will be collected during clinic visit and contacting patients in a determined protocol for the following 6 weeks after steroid injection.After approval of the study, data will collected from participants over a period of 6 weeks follow up; the whole study will be conducted over a total of 2 years.Since the study will not conduct any further test to participants and follow up regimen will only state pain related to the specific condition (De Quervain tenosynovitis) and quick-DASH score, it will not result in any anticipated/unanticipated incidental findings, therefore participants will not be recontacted.
Eligibility Criteria
Participants of the study will be selected by attending physician in Hand and Reconstructive Microsurgery outpatient clinic. Estimated sample size is 50 patients.Statistical power calculation (error type II) is 0.8The Kaplan-Meier product-limit method will be used to estimate the rates of freedom from recurrence of symptoms. Confidence intervals for Kaplan-Meier survivorship functions will be based on Greenwood's variance estimated. A multivariable Cox proportional hazards regression model is planned to identify independent predictors of outcome.
You may qualify if:
- \>21 years old
You may not qualify if:
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National University Hospital
Singapore, 119074, Singapore
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Renita Sirisena
National University Hospital, Singapore
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 14, 2022
First Posted
March 2, 2022
Study Start
March 14, 2019
Primary Completion
December 1, 2022
Study Completion
December 1, 2022
Last Updated
March 2, 2022
Record last verified: 2022-02